Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2019-2024 provides the reader with the following key benefits:

 

• In-depth understanding of clinical stage deal trends since 2019
• Access to headline, upfront, milestone and royalty data
• Comprehensive access to over 1,800 clinical stage deals together with contract documents if available
• Detailed access to actual clinical stage deals entered into by the leading 25 big pharma and big biotech companies along with other biopharma companies
• Analysis of the structure of clinical stage agreements with numerous real life case studies
• Identify leading clinical stage deals by value since 2019
• Identify the most active clinical stage dealmakers since 2019
• Full listing of clinical stage deals by company A-Z, phase of development, deal type, therapy and technology focus
• Understand the key deal terms companies have agreed in previous deals      
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Why do companies partner clinical stage compounds?

 

2.1. Introduction

2.2. The role of clinical stage partnering

2.2.1. In-licensing at clinical stage

2.2.2. Out-licensing at clinical stage

2.3. Difference between phase I, II and III stage deals

2.4. Reasons for entering into clinical stage partnering deals

2.4.1. Licensors reasons for entering clinical stage deals

2.4.2. Licensees reasons for entering clinical stage deals

2.5. The future of clinical stage partnering deals

 

Chapter 3 – Clinical stage deal strategies and structure

 

3.1. Introduction

3.2. At what stage do companies partner?

3.2.1. Partnering early in pharmaceutical/biotech

3.2.1.1. Discovery and preclinical stage partnering case studies

3.2.1.1.a. Case study 1

3.2.1.1.b. Case study 2

3.2.1.1.c. Case study 3

3.2.1.1.d. Case study 4

3.2.2. Partnering later in pharmaceutical/biotech

3.2.2.1. Clinical stage partnering case studies

3.2.2.1.a. Case study 5

3.2.2.1.b. Case study 6

3.2.2.1.c. Case study 7

3.2.2.1.d. Case study 8

3.3. Early and later stage partnering – a risk/cost comparison

3.4. What do companies spend on clinical stage partnering?

3.5. Pure versus multi-component partnering deals

3.6. Pure licensing agreement structure

3.6.1. Example pure licensing agreements

3.6.1.a. Case study 9

3.6.1.b. Case study 10

3.7. Multicomponent clinical stage partnering agreements

3.7.1. Example multicomponent clinical stage clauses

3.7.1.a. Case study 11

 

Chapter 4 – Clinical stage partnering payment strategies

 

4.1. Introduction

4.2. Clinical stage payment strategies

4.3. Payment options

4.3.1. Headline values

4.3.2. Upfront payments

4.3.2.1. Conditionality of upfront payments

4.3.3. Loans

4.3.4. Convertible loans

4.3.5. Equity

4.3.6. R&D funding

4.3.7. Licensing fees

4.3.8. Milestone payments

4.3.9. Royalty payments

4.3.9.1. Issues affecting royalty rates

4.3.9.2. Royalties on combination products

4.3.9.2.a. Case study 12

4.3.9.3. Guaranteed minimum/maximum annual payments

4.3.9.4. Royalty stacking

4.3.9.5. Royalties and supply/purchase contracts

4.3.10. Quids

4.3.11. Option payments

 

Chapter 5 – Trends in clinical stage deal making

 

5.1. Introduction

5.2. Clinical stage partnering over the years

5.2.1. Trends in phase I deals since 2019

5.2.1.1. Attributes of phase I deals

5.2.2. Trends in phase II deals since 2019

5.2.2.2. Attributes of phase II deals

5.2.3. Trends in phase III deals since 2019

5.2.3.1. Attributes of phase III deals

5.3. Clinical stage partnering by deal type

5.4. Clinical stage partnering by disease type

5.5. Partnering by clinical stage technology type

5.6. Clinical stage partnering by most active company since 2016

 

Chapter 6 – Payment terms for clinical stage partnering

 

6.1. Introduction

6.2. Guidelines for clinical stage payment terms

6.2.1. Upfront payments

6.2.2. Milestone payments

6.2.3. Royalty payments

6.3. Clinical stage payment terms – deal data analysis

6.3.1. Public data

6.3.2. Survey data

6.4. Payment terms analysis

6.4.1. Clinical stage partnering headline values

6.4.2. Clinical stage deal upfront payments

6.4.3. Clinical stage deal milestone payments

6.4.4. Clinical stage royalty rates

6.5 Clinical stage median financials

6.5.1. Clinical stage headline value

6.5.2. Clinical stage upfront value

6.5.3. Clinical stage milestone value

6.5.4. Clinical stage royalty value

 

Chapter 7 – Leading clinical stage deals

 

7.1. Introduction

7.2. Top clinical stage deals by value

 

Chapter 8 – Top 25 most active clinical stage dealmakers

 

8.1. Introduction

8.2. Top 25 most active clinical stage dealmakers

 

Chapter 9 – Clinical stage partnering contracts directory

 

9.1. Introduction

9.2. Clinical stage deals with contracts since 2016

 

Chapter 10 – Clinical stage deal making by development stage

 

10.1. Introduction

10.2. Deals by clinical stage

Phase I

Phase II

Phase III

Regulatory

 

Appendices

 

Appendix 1 – Clinical stage dealmaking by companies A-Z

Appendix 2 – Clinical stage dealmaking by industry sector

Appendix 3 – Clinical stage dealmaking by stage of development

Appendix 4 – Clinical stage dealmaking by therapy area

Appendix 5 – Clinical stage dealmaking by technology type

 

About Wildwood Ventures

 

Current Partnering

Current Agreements

Recent report titles from Current Partnering

 

Table of figures

Figure 1: Definition of clinical phases in dealmaking

Figure 2: Components of the pure licensing deal structure

Figure 3: Payment options for clinical stage partnering deals

Figure 4: Issues affecting royalty rates

Figure 5: Clinical stage partnering by deal type since 2019

Figure 6: Clinical stage partnering by disease type since 2019

Figure 7: Clinical stage partnering by technology type since 2019

Figure 8: Top 25 most active clinical stage dealmakers, 2019 - 2024

Figure 9: Review of upfront payments for clinical stage deals

Figure 10: Review of milestone payments for clinical stage deals

Figure 11: Review of royalty payments for clinical stage deals

Figure 12: Clinical stage deals with a headline value

Figure 13: Clinical stage deals with an upfront value

Figure 14: Clinical stage deals with a milestone value

Figure 15: Clinical stage deals with a royalty rate value

Figure 16: Top clinical stage deals by value since 2019

Figure 17: Most active clinical stage dealmakers 2019 - 2024

Pricing options

• $3,995: single-user
• $5,995: 2-5 users
• $7,995: Corporate (unencrypted PDF)

 

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

Sales Support

If you have any questions about your report, we will do our best to resolve your query. Contact us direct.

Total Trust

Current Partnering is part of Biopharma Research Ltd., based in York, United Kingdom. We have been trading successfully online since 2012 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

1ST Biotherapeutics, 2cureX, 3D Medicines, 3M, 3SBio, 4D Pharma, 4Living Biotech, 4P-Pharma, 4P Therapeutics, 4SC, 9 Meters Biopharma, Aadi Bioscience, AazeinTx, AB2 Bio, Abbisko Therapeutics, Abbott Laboratories, Abbvie, Abcam, ABEC, AbelZeta Pharma, Abeona Therapeutics, Abliva, ABVC BioPharma, Acasti Pharma, Acelrx Pharmaceuticals, Acelyrin, Acerta Pharma, Acer Therapeutics, Achilles Therapeutics, Acibadem University, AC Immune, Aclipse Therapeutics, Acrivon Therapeutics, Acrotech Biopharma, Actinium Pharmaceuticals, ActualEyes, Actuate Therapeutics, Acturum Life, Actym Therapeutics, Acumen Pharmaceuticals, Adagene, Adagio Therapeutics, Adamis Pharmaceuticals, Adaptimmune, Adaptive Phage Therapeutics, ADC Therapeutics, Addario Lung Cancer Medical Institute, Adhera Therapeutics, Adial Pharmaceuticals, Adimune, Adiso Therapeutics, Adlai Nortye, adMare BioInnovations, Advaccine Biotechnology, Advanced Regenerative Manufacturing Institute, Advanced Technology International, Advanz Pharma, Advaxis, Advent International, Adverum Biotechnologies, Aeglea BioTherapeutics, Aeromics, Aerpio Pharmaceuticals, AffaMed Therapeutics, Affibody, Affimed Therapeutics, AFFiRiS, AGC Biologics, Agenus Bio, Agilent Technologies, Agios Pharmaceuticals, AgonOx, AIM ImmunoTech, AimMax Therapeutics, AiPharma Global Holdings, Ajinomoto Bio-Pharma Services, AJU Pharma, Akcea Therapeutics, Akebia Therapeutics, Akeso Biopharma, Akili Interactive Labs, AKL Research and Development, Akron Biotechnology, Akston Biosciences, Albany Molecular Research, Aldevron, Alector, Alexion Pharmaceuticals, Alfasigma, Algernon Pharmaceuticals, Aligos Therapeutics, Alkermes, Allarity Therapeutics, Allecra Therapeutics, Allegro Ophthalmics, Alliance For Clinical Trials In Oncology, Alligator Bioscience, Allogene Therapeutics, Allorion Therapeutics, Almac Group, Almirall, Alnylam Pharmaceuticals, Alphamab Biopharmaceuticals, Alphamab Oncology, Alpine Immune Sciences, Altasciences, Altimmune, Altum Pharmaceuticals, Alume Biosciences, Alvogen, Alvotech, ALX Oncology, Alzamend Neuro, AlzeCure Pharma, Alzheimer's Drug Discovery Foundation, Alzheon, AlzProtect, AM-Pharma, Amal Therapeutics, Ambiopharm, American National Multiple Sclerosis Society, Amgen, Amicus Therapeutics, Amneal Pharmaceuticals, AMO Pharma, Amplyx Pharmaceuticals, Amygdala Neurosciences, Amylyx Pharmaceuticals, Amyndas Pharmaceuticals, Amytrx Therapeutics, AN2 Therapeutics, ANANDA Scientific, AnaptysBio, Anergis, Angelini Pharma, AnGes MG, Angion Biomedica, AnHeart Therapeutics, Anixa Biosciences, Ankyra Therapeutics, AnnJi Pharmaceutical, Annovis Bio, Antengene, Anteris Bio, Anthem, Antibe Therapeutics, Antios Therapeutics, AOBiome Therapeutics, Apeiron Biologics, Apellis Pharmaceuticals, Apexian Pharmaceuticals, Apexigen, Aphex BioCleanse Systems, Apollomics, Apollo Therapeutics, Appili Therapeutics, Applied Biology, Applied Therapeutics, AprilBio, Aptahem, Aptinyx, Aptose Biosciences, Aravive Biologics, Arbormentis, Arbutus, Arcellx, Arch Oncology, Arctic Therapeutics, Arctic Vision, Arcturus Therapeutics, Arcus Biosciences, Arecor, Arena Pharmaceuticals, Ariana Pharma, Ariceum Therapeutics, Aridis Pharmaceuticals, ARISE MD Integrative Medicine & Surgery, Aristea Therapeutics, Armata Pharmaceuticals, Arrevus, ArriVent Biopharma, Arrowhead Pharmaceuticals, ARTBIO, Artelo Biosciences, Artiva Biotherapeutics, ARTMS Product, Aruvant Sciences, Arvelle Therapeutics, Arvinas, Asahi Kasei, Asceneuron, Ascentage Pharma, Ascletis, Asher Biotherapeutics, Ashion Analytics, Asieris MediTech, ASKA Pharmaceuticals, Aslan Pharma, Aspen Neuroscience, Assembly Biosciences, Association for Frontotemporal Degeneration, Astellas Pharma, Astellas Pharma US, Astex Pharmaceuticals, AstraZeneca, Asymchem Laboratories, ATAI Life Sciences, Atara Biotherapeutics, Atea Pharmaceuticals, Athena Pharmaceutiques, Athenex, Athira Pharma, Atlantic Healthcare, ATMA Journey Centers, Atrapos Therapeutics, aTyr Pharma, Auditus, AUM Biosciences, AUM Biotech, Aurobindo Pharma, Australian and New Zealand Children’s Haematology / Oncology Group, Autism Impact Fund, Autobahn Therapeutics, Avacta, Avalo Therapeutics, Avance Clinical, Avania, Avenue Therapeutics, Avenzo Therapeutics, AVEO Oncology, Aveta Biomics, Avid Bioservices, AVM Biotechnology, Awakn Life Sciences, Axovant Gene Therapies, Axovia Therapeutics, Axsome Therapeutics, Ayala Pharmaceuticals, Azura Ophthalmics, AzurRx BioPharma, Bachem, Baili Biopharmaceutical, Baker Brothers Investments, Baliopharm, Banner Alzheimer's Institute, Barbara Ann Karmanos Cancer Institute, Basilea Pharmaceutica, Battelle, Bausch & Lomb, Bausch Health Companies, Bavarian Nordic, Baxter International, Bayer, Baylor College of Medicine, BeiGene, Beijing InnoCare Pharma, Beijing SL Pharma, Beijing Tide Pharmaceutical, Belle.ai, Benuvia Therapeutics, Be The Match BioTherapies, BetterLife Pharma, Better Therapeutics, Beverly Hills Cancer Center, Beyond Cancer, Bharat Biotech, Bial, Bicycle Therapeutics, Bill and Melinda Gates Foundation, Binex, Bio-Techne, Bio-Thera Solutions, BioAge Labs, BioAtla, BioBlast Pharma, Biocept, BioCity Biopharma, Biocon, BioCorRx, BioCryst Pharmaceuticals, Biodesix, Biodexa Pharmaceuticals, Biodextris, BioEclipse Therapeutics, BioElpida, Biofabri, Bioforum, Biogen, BioGenetics, Biohaven Pharmaceuticals, BioInvent, BioKey, Biokin Pharmaceutical, Biolexis, BiolineRX, BioLink Life Sciences, Biological E, BioMatrix Specialty Pharmacy, Biomedical Advanced Research and Development Authority, BioMed Valley Discoveries, Biomerica, Biomica, Biomunex Pharmaceuticals, BiomX, Bioncotech Therapeutics, Bioniz Therapeutics, BioNova Pharmaceuticals, BioNTech, BioPharma Services, bioRASI, BioRestorative Therapies, BioSenic, BioSense Global, BioSight, Biosplice, Biotechnology Industry Research Assistance Council, Biotheus, BioVaxys, BioVectra, BioVersys, BioVie, BioXcel, BJ Bioscience, Blackstone, Blanver, Bliss Biopharmaceutical, Bloom Science, Bluebird Bio, Blue Note Therapeutics, Blueprint Medicines, Boehringer Ingelheim, Bold Therapeutics, Bolt Biotherapeutics, Bone Biologics, Bone Therapeutics, BostonGene, Boston Immune Technologies and Therapeutics, Boston Pharmaceuticals, Botanix Pharmaceuticals, Boundless Bio, Bpifrance, Brainomix, BrainStorm Cell Therapeutics, Braintree Laboratories, Brammer Bio, BriaCell Therapeutics, Brickell Biotech, BridgeBio Pharma, Bridge Biotherapeutics, Brigham and Women's Hospital, Brii Biosciences, Bristol-Myers Squibb, Brown University, BryoLogyx, Burning Rock, Butantan Institute, Byondis, Cabaletta Bio, Cadila Pharmaceuticals, Caelum Biosciences, Caeregen Therapeutics, Calder Biosciences, Calian Group, Calidi Biotherapeutics, California Institute for Regenerative Medicine, Calithera Biosciences, Calliditas Therapeutics, Can-Fite BioPharma, Canadian Neuromuscular Disease Registry, CanariaBio, Cancer Focus Fund, Cancer Prevention and Research Institute of Texas, Cancer Research UK, CanCure, Candel Therapeutics, Cantargia, Cantex Pharmaceuticals, Capricor Therapeutics, Cara Therapeutics, CARB-X, Cardiff Oncology, Cardinal Health, Care Access Research, Caris Life Sciences, Carisma Therapeutics, Carrick Therapeutics, CARsgen, CASI Pharmaceuticals, Cassava Sciences, Catabasis Pharmaceuticals, Catalent, Catalyst Clinical Research, Catalyst Pharmaceuticals, CB2 Therapeutics, CCT Research, Ceapro, Cedar Clinical Research, Cedars-Sinai Medical Center, Celcuity, Celiac Disease Foundation, Cellares, Cell Cure Neurosciences, Cellectis, Cellenkos, Cellular Biomedicine, CellVax Therapeutics, Celonic, Cend Therapeutics, Center for Breakthrough Medicines, Centogene, Centrexion, Cerecor, CG Oncology, Charak Foundation, Charles River Laboratories, Checkmate Pharmaceuticals, ChemoCentryx, Chemomab Therapeutics, Chengdu Kanghua Biological Products, Chi-Med, Chiesi Farmaceutici, Chime Biologics, Chimeric Therapeutics, Chimerix, China Medical System, China Resources Sanjiu Medical and Pharmaceutical, Chipscreen NewWay Biosciences, Chong Kun Dang, Chongqing Jingdong Pharmaceutical, Chugai Pharmaceutical, CicloMed, Cidara Therapeutics, CinCor Pharma, Cipla, Circio, Circuit Clinical, CIRION BioPharma Research, City of Hope, City of Hope Comprehensive Cancer Center, Clarity Pharmaceuticals, Clearmind Medicine, Cleave Therapeutics, Clementia Pharmaceuticals, Clene Nanomedicine, Cleveland Clinic, Clinical Trial and Consulting Services, Clinica Universidad Navarra, Clinigen, Clinilabs, Clinlogix, Clover Biopharmaceuticals, Clovis Oncology, CMAB Biopharma, Cmed, CMG Pharmaceutical, CNS Pharmaceuticals, Coalition for Epidemic Preparedness Innovations, Cobra Biologics, Cocrystal Pharma, Codagenix, Codexis, Coeptis Pharmaceuticals, Coeptis Therapeutics, Cognition Therapeutics, Cognito Therapeutics, Coherus Biosciences, Columbia University, Combangio, Commonwealth of Pennsylvania, Compass Therapeutics, Compugen, Conatus Pharmaceuticals, Concentric Analgesics, Conduit Pharmaceuticals, Confo Therapeutics, Connect, ConSynance Therapeutics, Context Therapeutics, Contineum Therapeutics, ContraFect, Convergent Therapeutics, COPD Foundation, CORAT Therapeutics, Corbus Pharmaceuticals, Corden Pharma, CoreRx Pharma, Cornell University, Corpometria Institute, Cortice Biosciences, Cosmo Pharmaceuticals, COUR Pharmaceutical, COVAXX, Creapharm, Crescendo Biologics, Crestone Pharma, Critical Path Institute (C-Path), Cromos Pharma, CryoPort, CSIR-Central Drug Research Institute, CSL Behring, CSPC Megalith Biopharmaceutical, CSPC Pharmaceutical Group, CS Pharmaceuticals, CStone Pharmaceuticals, Cue Biopharma, Cugene, Cullinan Oncology, Cumberland Pharmaceuticals, Curavit Clinical Research, CUREator, Curebase, Cure Stat Rx, Cures Within Reach, Curetis, CureVac, Curis, Curium, Curon Biopharmaceutical, Curtana Pharmaceuticals, CyanVac, Cybin, Cybrexa Therapeutics, Cyclerion Therapeutics, Cyclo Therapeutics, Cyprium Therapeutics, Cystic Fibrosis Foundation, Cytiva, CytoAgents, Cytodyn, Cytokinetics, Cytovance Biologics, Cytovation, Cyxone, D&D Pharmatech, Daewoong Pharmaceutical, Daiichi Sankyo, Dalhousie University, Dana-Farber Cancer Institute, Danish Cancer Society Research Center, Dare Bioscience, DAS Therapeutics, Day One Biopharmaceuticals, DCPrime, Debiopharm, Deciphera Pharmaceuticals, Defender Pharmaceuticals, Defense Health Agency (US), Denovo Biopharma, Department of Defense, Department of Veterans Affairs, Dermapharm, Dermavant Sciences, Dermira, Develco Pharma, Deverra Therapeutics, Diaccurate, Diamond Therapeutics, Diamyd Medical, Dicerna Pharmaceuticals, Diffusion Pharmaceuticals, Diversigen, Dong-A Pharmaceutical, Dong-A ST, Dr. Falk Pharma, Dr. Reddy's Laboratories, Dragonfly Therapeutics, DRI Capital, DSG, DualityBio, Duchenne UK, Duke-NUS Graduate Medical School Singapore, Duke Clinical Research Institute (DCRI), Dutch Emotional Brain, DyDo Pharma, Dynacure, DynamiCure Biotechnology, Dynavax Technologies, Dyne Therapeutics, DynPort Vaccine Company, Eagle Pharmaceuticals, Eccogene, Eczacıbasi-Monrol, Edith Wolfson Medical Center, eFFECTOR Therapeutics, EGeen, EicOsis, Eidos Therapeutics, Eiger BioPharmaceuticals, Eikonizo Therapeutics, Eikon Therapeutics, EIP Pharma, Eisai, ElevateBio, Elevation Oncology, Elicio Therapeutics, Eli Lilly, Elixirgen, Ellipses Pharma, Eloxx Pharmaceuticals, Elpiscience, Eluminex Biosciences, Emerald Innovations, Emergent BioSolutions, Emergex Vaccines, Emmes Group, Emory University, Emtora Biosciences, EmVenio Research, ENA Respiratory, Endo International, EndoLogic, Endpoint Health, ENDRA Life Sciences, Enlivex, Ensysce Biosciences, Enterin, Enteris Biopharma, Enterome Bioscience, Enterprise Therapeutics, Entheon Biomedical, Entos Pharmaceuticals, Enveric Biosciences, Enzychem Lifesciences, EOC Pharma, EpicentRx, Epic Sciences, EQRx, Equillium, Equinox Science, Erasca, Erasmus University Medical Center, Esperion Therapeutics, ESSA Pharma, ES Therapeutics, Eton Pharmaceuticals, Eucure Biopharma, Eunice Kennedy Shriver Institute of Child Health and Human Development, Eureka Eurostars, Eurocine Vaccines, Eurofins Scientific, European Biomedical Research Institute of Salerno, European Commission, European Union, EUSA Pharma, Evaxion Biotech, Everest Medicines, Evergreen Theragnostics, Evergreen Therapeutics, EverInsight Therapeutics, Eversana, Evolution Research Group, Evommune, Evopoint Biosciences, Evotec, Ewopharma, Excellmab, Excision BioTherapeutics, Exelixis, Exothera, Eyenovia, EyePoint Pharmaceuticals, F-Star Therapeutics, F4 Pharma, Famy Life Sciences, Fannin, Fareva Holding, FarmaMondo Group, Fedora Pharmaceuticals, Feinstein Institute for Medical Research, Ferrer, Ferring Pharmaceuticals, Fibrogen, FightMND, Filament Health, Finch Therapeutics, First Wave Bio, FivepHusion, Flatiron Health, Florence, Fluence, FLX Bio, Food and Drug Administration (FDA), Forbius, ForDoz Pharma, Foreseen Biotechnology, Foresee Pharmaceuticals, Forge Biologics, FORMA Therapeutics, Formosa Pharmaceuticals, Fortis Therapeutics, Fortrea, Forty Seven, Fosun Pharmaceutical, Foundation Medicine, Fox Chase Cancer Center, Fred Hutchinson Cancer Research Center, Freeline Therapeutics, Freenome, Frequency Therapeutics, Fresh Tracks Therapeutics, Freya Pharma Solutions, Frontage Clinical Services, Frontier Biotech, Fujifilm, Fujifilm Diosynth Biotechnologies, Fuji Yakuhin, Fulcrum Therapeutics, Fusion Pharmaceuticals, FutureChem, G1 Therapeutics, G42 Healthcare, GABA Therapeutics, Gain Therapeutics, Galapagos, Galecto, Galimedix Therapeutics, Gamaleya National Center, Gamida Cell, GAVI Alliance, GC Pharma, Gedeon Richter, GEICAM, Gemelli Teaching Hospital, Gemini Therapeutics, GEMMA Biotherapeutics, Gemphire, GEn1E Lifesciences, Genascence, Genelux, Genentech, Geneoscopy, GenesisCare, Genethon, Genetika+, Genfit, GenFleet Therapeutics, Genome and Company, Genosity, GenScript Biotech, GenScript ProBio, George Clinical, Georgetown University, Georgiamune, GeoVax, German Federal Ministry of Education and Research, German Government, Giiant Pharma, Gilead Sciences, Glaukos, Glenmark Pharmaceuticals, Glenmark Pharmaceuticals S.A., Global Coalition for Adaptive Research, Global Medical Solutions, Gloria Biosciences, GlycoMimetics, Glycostem Therapeutics, Glycotope Biotechnology, GOG Foundation, Gore Range Capital, Gossamer Bio, Government of Canada, Government of France, Government of India, Government of Israel, Government of Netherlands, Government of Switzerland, GPCR Therapeutics, Granata Bio, Grand River Aseptic Manufacturing, Graviton Bioscience, Great Ormond Street Hospital (GOSH), Green Valley Pharmaceutical, Greenwich LifeSciences, Grey Wolf Therapeutics, Grifols, Gritstone Bio, Groupe d'OncologieRadiothérapie Tête Et Cou, Groupe Francophone des Myélodysplasies, Grunenthal, GSK, GT Biopharma, GT Medical Technologies, Guardant Health, Gurnet Point Capital, Hadassah Medical Center, HaemaLogiX, Haisco Pharmaceutical, HalioDx, Halix, Halucenex Life Sciences, Handok Pharmaceuticals, Hangzhou Highlightll Pharmaceutical, Hangzhou Zhongmei Huadong Pharmaceutical, Hanmi Pharmaceutical, Hansa Biopharma, HanX Biopharmaceuticals, Harbour Biomed, Harmony Biosciences, Harpoon Therapeutics, Harrow Health, Harvard Medical School, Harvard University, Hasten Biopharmaceutic, Haystack Oncology, HCW Biologics, Healis Therapeutics, Healthcare Royalty Partners, Healx, Helmholtz Zentrum Munchen, Helocyte, Helsinn Healthcare, Helsinn Therapeutics, Hemogenyx, Hengenix Biotech, Henlius Biotech, Hepalys Pharma, Hepion Pharmaceuticals, HepQuant, HiberCell, HIBio, HiFiBio, Highlight Therapeutics, Hikma Pharmaceuticals, HilleVax, Hillhurst Biopharmaceuticals, HistoIndex, HK inno.N, HMNC Brain Health, Hoffmann La Roche, Hookipa Pharma, Horizon Therapeutics, Hoth Therapeutics, Houston Pharmaceuticals, Huadong Medicine, Hubro Therapeutics, Humanigen, Hummingbird Bioscience, Huons, Hutchmed, Huyabio International, hVIVO, Hygieia, Hyloris Pharmaceuticals, Hypospray Pharma, I-mab, IACTA Pharmaceuticals, IAMA Therapeutics, IBSA Group, Icahn School of Medicine at Mount Sinai, Ichnos Sciences, Icon, IDEAYA Biosciences, Idera Pharmaceuticals, Idorsia, IDT Biologika, IGM Biosciences, Ikena Oncology, Iksuda Therapeutics, ILiAD Biotechnologies, Image Analysis, ImaginAb, Imeka, Immatics Biotechnologies, Immedica, Immix Biopharma, ImmPACT Bio, Immune-Onc Therapeutics, ImmuneOnco Biopharmaceuticals, Immune Regulation, ImmuNext, Immunic, Immunicom, Immunis, ImmunityBio, ImmunoBrain Checkpoint, ImmunoCellular Therapeutics, Immunocore, ImmunoForge, ImmunoGen, Immunogenesis, Immunome, Immunomedics, Immunomic Therapeutics, ImmunoPrecise Antibodies, Immunovia, Immusoft, Immutep, ImmVira, IMPACT Therapeutics, Imperial College London, Impression Healthcare, Imugene, IMV, InCarda Therapeutics, IncellDx, Incyte, InDex Pharmaceuticals, Indivior, Inflection Biosciences, iNGENu, Inivata, Inmagene Biopharmaceuticals, INmune Bio, Innosuisse, Innovare, Innovate Biopharmaceuticals, Innovate UK, Innovation Pharmaceuticals, Innovent Biologics, Inotrem, Inovio, Inovio Pharmaceuticals, Inserm, Insilico Medicine, Inspirna, Instil Bio, Institut Bergonie, Institut Curie, Institute of Cancer Research, Institute of Human Virology, Institute of Molecular Biology of Paraná (IBMP), Institut Gustave Roussy, Institut Pasteur, Intas Pharmaceuticals, IntelGenx, Intensity Therapeutics, International Vaccine Institute (IVI), Intrommune Therapeutics, Invectys, Inventiva, InxMed, IO Biotech, iOnctura, Ionetix, Ionis Pharmaceuticals, Ionova, Ipsen, IQVIA, IriSys, IRLAB, Ironwood Pharmaceuticals, Ischemix, Isofol Medical, ISOThrive, Israeli National Authority for Technological Innovation, Italian Association for the Study of Pancreas, Italian Government, iTeos Therapeutics, Iterion Therapeutics, ITM Isotopen Technologien, iVeena Delivery Systems, Iveric Bio, Ivy Brain Tumor Center, Ixaka, IXICO, Jacobio Pharmaceuticals, Jaguar Health, Jain Foundation, JanOne, Janssen Biotech, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Research & Development, Japan Government, Japan Tobacco, Jasper Therapeutics, Jazz Pharmaceuticals, JCR Pharmaceuticals, jCyte, Jemincare, Jenner Institute, Jesse's Journey, Jiangsu Alphamab, Jiangsu Aosaikang Pharmaceutical, Jiangsu Hansoh Pharmaceutical, Jiangsu Hengrui Pharmaceuticals, Jiangsu Wuzhong Pharmaceutical, Ji Xing Pharmaceuticals, JMT-Bio, Johns Hopkins University, Johnson & Johnson, Joincare Pharmaceutical, Journey Medical, Jumpcan Pharmaceutical, Juno Therapeutics, Junshi Biosciences, Juvenile Diabetes Research Foundation, JW Pharmaceutical, Kabuki Syndrome Foundation, Kadmon Pharmaceuticals, KAHR Medical, Kaken Pharmaceutical, Kalbe Genexine Biologics, Kaleido Biosciences, KaliVir Immunotherapeutics, Kanazawa University, Kaneka, KARE Biosciences, Karolinska Institute, Karuna Therapeutics, Karyopharm Therapeutics, Kashiv BioSciences, Kazia Therapeutics, KBP BioSciences, Keck School of Medicine of USC, KemPharm, Kennedy Krieger Institute, Keros Therapeutics, Ketabon, Keymed Biosciences, Kezar Life Sciences, KGK Science, Kiadis Pharma, Kineta, Kiniksa Pharmaceuticals, Kinnate Biopharma, Kintor, Kirin Brewery, Kiromic Biopharma, Kissei Pharmaceutical, Kite Pharma, Knight Therapeutics, Kodiak Sciences, Koneksa Health, Korea Drug Development Fund, Kowa, Krankenhaus Nordwest, KSQ Therapeutics, Kukbo, Kumquat Biosciences, Kura Oncology, KVK-Tech, Kyorin Pharmaceutical, Kyowa Hakko Kirin, Kyowa Hakko Kogyo, Kyverna Therapeutics, LabConnect, Laboratoires Thea, Laboratorios Farmaceuticos Rovi, Laekna, LakePharma, Landos Biopharma, LaNova Medicines, Lantern Pharma, Lantheus Holding, Lantheus Medical Imaging, Launch Therapeutics, Laurent Pharmaceuticals, Laurus Labs, Lava Therapeutics, Laxisam, Lee's Pharmaceutical, Lee Moffitt Cancer Center, Legend Biotech, LegoChem Biosciences, Lehigh Valley Health Network, Leiden University, LENZ Therapeutics, LEO Pharma, Lepu Biopharma, Leucid Bio, Leukemia & Lymphoma Society, Levolta Pharmaceuticals, LEXEO Therapeutics, Lexicon Pharmaceuticals, LG Chem, LG Life Sciences, LianBio, LIB Therapeutics, LifeArc, Ligand Pharmaceuticals, LimmaTech Biologics, Lineage Cell Therapeutics, LineaRx, Link Health, Link Immunotherapeutics, LinKinVax, Linnaeus Therapeutics, LIPAC Oncology, Lipidor, Lipomedix Pharmaceuticals, Lisata Therapeutics, Lixte Biotechnology, Longeveron, Lonza, Lotus Pharmaceuticals, Ludwig Institute for Cancer Research, Lumos Pharma, Lundbeck, Lung Cancer Initiative, Lung Therapeutics, Lupus Therapeutics, Lynk Pharmaceuticals, Lysogene, Lysosomal Therapeutics, Lytix Biopharma, Lyvgen Biopharma, Macrogenics, Magenta Therapeutics, MAIA Biotechnology, Mallinckrodt Pharmaceuticals, Mapp Biopharmaceutical, Marker Therapeutics, Maruho, Massachusetts General Hospital, Massachusetts Institute of Technology, Mass General Brigham, Matrix Biomed, Matrix Medical Network, Maverick Therapeutics, Maxcyte, MaxiVAX, Mayo Clinic, McNeil Consumer Pharmaceuticals, McQuade Center for Strategic Research and Development, MD Anderson Cancer Center, Medac, Medical Research Council, Medical Technology Enterprise Consortium, Medicenna Therapeutics, Medicines Development for Global Health, Medicines Patent Pool Foundation, MediciNova, Medidata Solutions, MediLink Therapeutics, Medison Pharma, Medivir, MediWound, Medsenic, Meiji Seika, MEI Pharma, Melinta Therapeutics, Melior Pharmaceuticals, Memorial Sloan Kettering Cancer Center, Menarini, Mendus, MentiNova, Merakris Therapeutics, Merck and Co, Merck KGaA, Merck Sharpe & Dohme, Mereo BioPharma, Merus, Mesoblast, Michael J Fox Foundation, Michigan Medicine, Microbion, Microbio Shanghai, Microbiotica, Micron Biomedical, MiMedx, Minaris Regenerative Medicine, MindMaze, Minerva Neurosciences, MinervaX, Ministry of Health, Ministry of Health (Israel), Ministry of Health, Labor and Welfare, Minoryx Therapeutics, Mirati Therapeutics, Mirum Pharmaceuticals, Mission Bio, Mitsubishi Tanabe Pharma, MMS, Moberg Pharma, Moderna, Modis Therapeutics, Molecular Templates, Moleculin Biotech, Molnlycke Health Care, Montreal Heart Institute, MoonLake Immunotherapeutics, MorphoSys, Mount Sinai Medical Center, MSD, MThera Pharma, Multidisciplinary Association for Psychedelics Studies, Mundipharma, Mustang Bio, Mycovia Pharmaceuticals, Mydecine Group, Myeloproliferative Neoplasm Research Consortium, Myovant Sciences, Myriad Genetics, Myung In Pharm, NacuGen Therapeutics, Nacuity Pharmaceuticals, Nanjing Leads Biolabs, Nanobiotix, Nanoform, NanoMab Technology, Nantes University, NantKwest, NASA, Nascent Biotech, Natera, National Brain Tumor Society, National Cancer Center, National Cancer Institute, National Centre for Research and Development, National Cheng Kung University, National Heart, Lung and Blood Institute, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal Diseases, National Institute of Child Health and Human Development, National Institute of Neurological Disorders and Stroke, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Drug Abuse (NIDA), National Institutes of Health, National Research Council Canada, National Research Council of Canada, National University Cancer Institute, Nationwide Children’s Hospital, Navega Therapeutics, Naveris, Navitor Pharmaceuticals, NCK, NEC, Nectin Therapeutics, Nektar Therapeutics, Nelum Pharma, Neogenomics, NeoImmuneTech, Neoleukin Therapeutics, NeoLumina Bioscience, Nephron Pharmaceuticals, NervGen Pharma, Nestle Health Science, NETRIS Pharma, NeuCyte, Neumentum, Neurimmune Therapeutics, NeurMedix, NeuroBo Pharmaceuticals, Neurocrine Biosciences, NeuroFront, Neurogastrx, NeuroGenesis, Neurolixis, Neurona Therapeutics, NeuroRx, NeuroSense Therapeutics, Neurotrope BioScience, NewAmsterdam Pharma, NewG Lab, New Hope Research Foundation, Newron Pharmaceuticals, Newsoara Biopharma, New York Cancer & Blood Specialists, Nexcella, Neximmune, NEXT Oncology, NFL Biosciences, NGM Biopharmaceuticals, Nicox, Nielsen BioSciences, NiKang Therapeutics, NImmune Biopharma, Nippon Shinyaku, NKGen Biotech, NKMax America, Nogra Pharma, Nordic Bioscience, Nordic Society of Gynaecological Oncology, NorthStar Medical Radioisotopes, Northway Biotechpharma, Northwell Health, Northwest Biotherapeutics, Northwestern University, Notable Labs, Nouscom, NovalGen, Novaliq, Novan Therapeutics, NovaQuest, Novaremed, Novartis, Novasep, Novavax, Novellus Biopharma, Noveome Biotherapeutics, Novo, Novocure, Novogene, Novo Nordisk, Novotech, Now Biopharma, Noxopharm, NRx Pharmaceuticals, Nuance Pharma, Nucleus RadioPharma, Numab, Nuvectis Pharma, Nuvisan Pharma Services, Nykode Therapeutics, NYU Grossman School of Medicine for Preclinical and Clinical Research, NYU Langone Medical Center, Oak Hill Bio, Oasmia Pharmaceutical, OBI Pharma, Oblato, ObsEva, Octapharma, Ocugen, Oculis, Ocumension Therapeutics, Ocuphire Pharma, Odeon Therapeutics, Ohara Pharma, Olatec Therapeutics, Olema Oncology, Oligomerix, Omeros, OncoC4, Oncoceutics, Oncoheroes Biosciences, OncoHost, OncoImmune, Oncologie, Oncology Venture, Oncolytics Biotech, OncoNano Medicine, Onconova Therapeutics, OncoResponse, OncoSec Medical, Oncotelic, OncoVent, OncoZenge, OncXerna Therapeutics, Onegevity, Oneness Biotech, OnKure, ONL Therapeutics, Ono Pharmaceutical, Onxeo, OpGen, Ora, Orano Med, Orbit Biomedical, Oregon Health Sciences University, Organon, Orgenesis, ORIC Pharmaceuticals, Orient EuroPharma, Orion, Orion Biotechnology, Orsenix, OrsoBio, Orum Therapeutics, Oryzon, OSE Immunotherapeutics, Osel, Osivax, Otsuka, Ottawa Health Research Institute, Ottawa Hospital Research Institute, Overland ADCT BioPharma, Overland Pharmaceuticals, Ovid Therapeutics, Owl Therapeutics, Oxford BioMedica, Oxford BioTherapeutics, Pacylex, Palisade Bio, Palobiofarma, Panbela Therapeutics, Panolos Bioscience, PanOptica, PanTher Therapeutics, Parexel, Parexel Biotech, Parkinson's UK, Parthenon Therapeutics, Partnership for Accelerating Cancer Therapies, Partner Therapeutics, Pascal Biosciences, Pasithea Therapeutics, Passage Bio, PathAI, Pathalys Pharma, Patheon, Pathos AI, PaxMedica, PDC*line Pharma, PDS Biotechnology, PellePharm, Peptilogics, Persephone Biosciences, Personal Genome Diagnostics, Personalis, Peter MacCallum Cancer Institute, Petra Pharma, Pfizer, Phanes Therapeutics, Pharco Pharma, PharmAbcine, Pharmaceutical Solutions, PharmaLogic, PharmaMar, Pharma Two B, Pharming Group, PhaseBio Pharmaceuticals, Phathom Pharmaceuticals, Phebra, Phenex, Philogen, Phio Pharmaceuticals, Phosplatin Therapeutics, Phost’in Therapeutics, PhysIQ, Pieris Pharmaceuticals, Pierre Fabre, Pinteon Therapeutics, Pionyr Immunotherapeutics, Piramal, Plexxikon, Pluristem Therapeutics, Plus Therapeutics, PlusVitech, PMV Pharma, PoC Capital, POINT Biopharma, Polaris Group, PoloMar Health, Polpharma, Polyphor, Poolbeg Pharma, Population Health Research Institute, Portage Biotech, Poseida Therapeutics, PPD, Precirix, Precision BioSciences, Precision for Medicine, Prelude Therapeutics, Presage Biosciences, Prestige BioPharma, Prime Therapeutics, Privo Technologies, Procare Health, Progenetics, Progenics Pharmaceuticals, Project to Accelerate New Treatments for Tuberculosis, Prokarium, Prometrika, Propella Therapeutics, ProQR Therapeutics, Protagonist Therapeutics, Prothena, ProtoKinetix, Provention Bio, Providence, Providence Cancer Institute, Providence Therapeutics, PSI CRO, Psyence Group, Psyence Therapeutics, PT Bio Farma, Pulmotect, Puma Biotechnology, PureTech Health, Purple Biotech, Q32 Bio, QBiotics, QED Therapeutics, Qiagen, Qilu Pharmaceutical, QSAM Biosciences, Qualigen, QuantHealth, Quantum Leap Health Care Collaborative, Quartesian Clinical Research, Quotient, QurAlis, Qurient, R-Pharm, Race Oncology, Radiomedix, Radiopharm Theranostics, Radius Health, Rafael Pharmaceuticals, Rain Oncology, Rambam Medical Center, Rancho Santa Fe Bio, RAPT Therapeutics, Ratio Therapeutics, Raziel Therapeutics, ReAlta Life Sciences, Reata Pharmaceuticals, Recipharm, Recludix Pharma, RedHill Biopharma, Redx Pharma, RefleXion Medical, Regenerative Medicine of Latin America, Regeneron Pharmaceuticals, Regenexx, Regenxbio, Regio Biosciences, Regnum, Regulus Therapeutics, Relay Therapeutics, Relief Therapeutics, Relife, Relmada Therapeutics, RemeGen, Renexxion, Rentschler Biotechnologie, Repare Therapeutics, Replimune, ReproCell, Reset Pharmaceuticals, Res Nova Bio, RespireRx Pharmaceuticals, Resverlogix, Retinagenix, Revance Therapeutics, ReveraGen BioPharma, reViral, Revive Therapeutics, Revolo Biotherapeutics, Revolution Medicines, Rexahn Pharmaceuticals, Rgene, Rhizen Pharmaceuticals, Rho, Rhythm Pharmaceuticals, Ribomic, Ribon Therapeutics, Rigel Pharmaceuticals, Ripple Therapeutics, Rising Pharmaceuticals, Rivus Wellness and Research Institute, RLS, Roche, Rocket Pharmaceuticals, Roivant Sciences, Rokote Laboratories, Romanian National Institute of Infectious Diseases, Roswell Park Cancer Institute, Royal Marsden Hospital, Royalty Pharma, Rugen Therapeutics, Rune Labs, Russian Direct Investment Fund, Rutgers University, Rxilient Biotech, Ryvu Therapeutics, Rznomics, SAB Biotherapeutics, Sagimet Biosciences, Salarius Pharmaceuticals, Salix Pharmaceuticals, SAMIL Pharm, Samsung Biologics, Samyang Biopharmaceuticals, Sanaria, Sandoz, Sangamo Therapeutics, Sanofi, SaNOtize Research and Development, Santhera Pharmaceuticals, Sapience Therapeutics, Sapu Bioscience, Sarah Cannon Research Institute, Sarepta Therapeutics, Savara Pharma, Scancell, Scandion Oncology, SciClone Pharmaceuticals, Science 37, Seagen, Seattle Genetics, Sebela Pharmaceuticals, Second Genome, Seelos Therapeutics, Seikagaku, Selecta Biosciences, Selexis, SELLAS Life Sciences Group, Sema4, Sen-Jam Pharmaceutical, Senju Pharmaceutical, Sensei Biotherapeutics, Sentynl Therapeutics, Seoul National University, Sequential Medicine, SERB Pharmaceuticals, Seres Therapeutics, Sermonix Pharmaceutical, Sernova, Serum Institute of India, Sesen Bio, Seven and Eight Biopharmaceuticals, SevenScore Pharmaceuticals, SFJ Pharmaceuticals, Shanghai Argo Biopharmaceutical, Shanghai ChemPartner, Shanghai Haini Pharmaceutical, Shanghai Public Health Clinical Centre, Sharp HealthCare, Shasqi, Shenogen Pharma, Shenzhen Chipscreen Biosciences, Shenzhen Kangtai Biological Products, Shenzhen Salubris Pharmaceuticals, Shionogi, Shionogi Pharma, Shirley Ryan AbilityLab, SIGA Technologies, Silence Therapeutics, Silk Road Therapeutics, Simcere Pharmaceuticals, Simcha Therapeutics, Singlomics Biopharmaceuticals, Singota Solutions, SinoMab Bioscience, Sinopharm Group Beijing HuaHong, Sinovac Biotech, Sintetica, Sionna Therapeutics, Sirnaomics, SIRS Therapeutics, Sirtex Medical, SiteOne Therapeutics, SK Biopharmaceuticals, SK Bioscience, Skye Bioscience, SmartCella, Smerud Medical Research, Societal CDMO, Sol-Gel, Solasia Pharma, Soligenix, Solural Pharma, Sonnet BioTherapeutics, SOPHiA Genetics, Soricimed Biopharma, Sorrento Therapeutics, Sorse Technology, Sosei, Sosei Heptares, SOTIO, Spanish Sarcoma Group, Specialised Therapeutics, Specialized Medical Services-oncology, Spectrum Pharmaceuticals, Sperogenix Therapeutics, Spero Therapeutics, Spinogenix, Spring Bank Pharmaceuticals, SpringWorks Therapeutics, Spruce Biosciences, Stallargenes, Stanford University, Stanford University School of Medicine, Starton Therapeutics, Statera Biopharma, Stealth BioTherapeutics, St Elizabeth Healthcare, SteroTherapeutics, St George Street Capital, Stimunity, Strados Labs, Strata Oncology, Streeterville Capital, Stuart Therapeutics, Sumitomo Pharmaceuticals, Summit Therapeutics, Sunovion Pharmaceuticals, Sun Pharmaceutical, Sunstone Capital, Sunstone Therapies, Supernus Pharmaceuticals, Supriya Lifescience, Surface Oncology, Sutro Biopharma, Suzhou Ribo Life Sciences, Suzhou Sinovent Pharmaceuticals, Swedish Orphan Biovitrum, Swedish Research Council, Swing Therapeutics, SymBio Pharmaceuticals, Symbiosis, Synairgen, Synaptogenix, Syndax Pharmaceuticals, Syneos Health, Synimmune, Synlogic, Syntrix Biosystems, Syros Pharmaceuticals, Systimmune, T-Cure Bioscience, T-MAXIMUM Biotech, T3D Therapeutics, Tabuk Pharmaceutical, Tachyon Therapeutics, TaiGen Biotechnology, Taiho, Taiwan Bio Therapeutics, TaiwanJ Pharmaceuticals, Takeda Pharmaceutical, Takeda Pharmaceuticals U.S.A, Targeted Therapy Technologies, Targovax, TargTex, Tarveda Therapeutics, Tasly Pharmaceuticals, Tavotek Biotherapeutics, TCR2 Therapeutics, Team Sanfilippo, TEDOR Pharma, Teijin, Telix Pharmaceuticals, Tempest Therapeutics, Tempus, Teon Therapeutics, Terns Pharmaceuticals, Terran Biosciences, TerSera Therapeutics, Tessa Therapeutics, Tetra Bio-Pharma, Teva Pharmaceutical Industries, Texcell, TFF Pharmaceuticals, Thea Open Innovation, The Frontiers in Congenital Disorders of Glycosylation Consortium, The International AIDS Vaccine Initiative, Themis Bioscience, Therabest, Theragent, Therapeutic Solutions International, Theratechnologies, Thermo Fisher Scientific, Thomas Jefferson University, Thorne Research, Tianjin CanSino Biotechnology, Tianjin JuveStar Biotech, Tiburio Therapeutics, TILT Biotherapeutics, TiumBio, Tiziana Life Sciences, Tolero Pharmaceuticals, TONIX Pharmaceuticals, Torii Pharmaceutical, Torque Therapeutics, TRACON Pharmaceuticals, TRACT Therapeutics, Transcenta, Transgene, TransThera, Travere Therapeutics, Treeway, Trethera, Trevena, Trevi Therapeutics, TrialSpark, TRIGR Therapeutics, Trillium Therapeutics, Trinity Pharmaceuticals, TriSalus Life Sciences, Triumvira Immunologics, TrovaGene, TRPharm, Tryp Therapeutics, Tufts Medical Center, TuHURA Biosciences, Turning Point Therapeutics, TWi Biotechnology, TYG Oncology, Tyligand Bioscience, Tyme Technologies, UbiVac, UCB, UK Government, Ultragenyx Pharmaceuticals, Unicycive Therapeutics, UNION Therapeutics, UniQure, United BioPharma, UnitedHealth, University College London, University Hospital Bispebjerg, University Medical Center Groningen, University of Alabama at Birmingham, University of Alberta, University of Auckland, University of Birmingham, University of Calgary, University of California, Davis, University of California Los Angeles, University of Cambridge, University of Florida, University of Kansas, University of Liverpool, University of Michigan, University of Minnesota, University of Nebraska, University of North Carolina, University of Oxford, University of Pennsylvania, University of Pittsburgh Medical Center, University of Rochester, University of Rochester Medical Center, University of Sydney, University of Virginia, University of Washington, University of Wisconsin, Unlearn, Urica Therapeutics, Urology San Antonio, US Army Medical Research and Material Command, US Government, Usher Syndrome Coalition, US Oncology, Utrecht University, Vaccinex, Vaccitech, Valneva, Valo Therapeutics, Vanderbilt University, Vaneltix Pharma, Varifarma, Vasomune Therapeutics, Vaxart, Vaxxinity, VBI Vaccines, VectivBio, Vedanta Biosciences, Veeva Systems, VenatoRx, Verastem, Vera Therapeutics, Verge Genomics, Verily, VerImmune, Verona Pharma, Verrica Pharmaceuticals, Vertex Pharmaceuticals, Veru, VGI Health Technology, Vial, Viatris, Vicore Pharma, Viewpoint Molecular Targeting, Vifor Pharma, Vigil Neuroscience, Vincera Pharma, Viracta Therapeutics, Vir Biotechnology, Virginia Catalyst, Virginia Tech Carilion Research Institute, Viriom, VistaGen Therapeutics, Vitalli Bio, Vivera Pharmaceuticals, Vivet Therapeutics, Voyager Therapeutics, vTv Therapeutics, Vyera Pharmaceuticals, Vyluma, Vyriad, Wacker Biotech, Wacker Chemie, Walgreens, Warpnine, WaVe Lifesciences, WAVE Life Sciences, Weill Cornell Medical College, Wellcome Trust, Wellmarker Bio, Werewolf Therapeutics, WideTrial, Wigen Biomedicine, WindMIL Therapeutics, Windtree Therapeutics, Winhealth Pharma Group, Worldwide Clinical Trials, WPD Pharmaceuticals, WuXi Advanced Therapies, Wuxi Apptec Laboratory Services, WuXi Biologics, Wuxi STA, X4 Pharmaceuticals, XBiotech, Xencor, Xenon Pharmaceuticals, Xequel Bio, Xiamen Amoytop Biotech, Xilio Therapeutics, Xlife Sciences, XNK Therapeutics, Xoma, Xortx Therapeutics, Xuanzhu Biopharma, XyloCor Therapeutics, Yale University, Yamo Pharmaceuticals, Yingli Pharma, Yisheng Biopharma, Yumanity Therapeutics, Yunnan Walvax Biotech, ZAI Laboratory, Zambon, Zealand Pharma, Zedira, Zenas BioPharma, Zenith Epigenetics, Zenoaq, Zentalis Pharmaceuticals, Zenyaku Kogyo, Zetagen Therapeutics, Zhaoke (Hong Kong) Ophthalmology Pharmaceutical, Zhejiang Doer Biotechnology, Zhittya Genesis Medicine, Zion Medical, Zion Pharmaceuticals, Zogenix, Zura Bio, Zydus Cadila, Zylo Therapeutics, Zymedi, Zymeworks, ZYUS Life Sciences, ZyVersa Therapeutics, ZZ Biotech

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.